Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients-Reference-Cited by-同舟云学术

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients

Published:2017-02 Issue: Volume:104 Page:131-133
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Juan Oscar,Popat Sanjay

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. First-line epidermal growth factor receptor (EGFR) kinase inhibitors for EGFR mutant non-small cell lung cancer: and the winner is;Juan;Clin. Oncol. (R. Coll. Radiol.),2016

2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N. Engl. J. Med.,2014

3. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J. Clin. Oncol.,2012

4. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases;Warth;Histopathology,2014

5. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort;Mazieres;J. Clin. Oncol.,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort;Current Oncology;2022-03-14

2. Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants;Cancer Medicine;2020-03-13

3. Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective;Current Oncology;2019-08-01

4. Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas;International Journal of Cancer;2018-12-03

5. Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis;Oncology Letters;2018-07-26